Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The companies clash over survival curve similarities – and differences.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
After ZW171's exit, ZW251 enters the clinic.
Petosemtamab's phase 2 data in this setting should come by the year end.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
